Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (31-40 of 161) with videos related to

Pageof 17
Sort By:
Cancers|June 22, 2023
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate CancerPeter H J Slootbeek, Iris S H Kloots, Inge M van Oort, et al.
British Journal of Clinical Pharmacology|September 8, 2017
Drug-drug interaction potential in men treated with enzalutamide: Mind the gapGuillemette Emma Benoist, Inge M van Oort, Stella Smeenk, et al.
British Journal of Clinical Pharmacology|August 26, 2021
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancerEmmy Boerrigter, Guillemette E Benoist, Joanneke K Overbeek, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2019
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokineticsFloor J E Lubberman, Guillemette E Benoist, Winald Gerritsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 9, 2021
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223Maarten J van der Doelen, Agnes Stockhaus, Yuanjun Ma, et al.
Nature Communications|April 24, 2023
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcomeJeroen H A Creemers, Ankur Ankan, Kit C B Roes, et al.
Therapeutic Advances in Medical Oncology|December 17, 2024
Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysisCatharina J P Op 't Hoog, Sabien J E Bosman, Emmy Boerrigter, et al.
Non-Coding RNA|December 22, 2022
The Androgen Regulated lncRNA <i>NAALADL2-AS2</i> Promotes Tumor Cell Survival in Prostate CancerLevi Groen, Viktor Yurevych, Harshitha Ramu, et al.
Clinical Nuclear Medicine|November 23, 2017
223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily PracticeMaarten J van der Doelen, Malou C P Kuppen, Marianne A Jonker, et al.
BMJ Open|May 19, 2021
Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCIAnke Richters, Richard P Meijer, Niven Mehra, et al.
Pageof 17

Showing results (31-40 of 161) with videos related to

Sort By:
Pageof 17
Cancers|June 22, 2023
Cross-Resistance between Platinum-Based Chemotherapy and PARP Inhibitors in Castration-Resistant Prostate CancerPeter H J Slootbeek, Iris S H Kloots, Inge M van Oort, et al.
British Journal of Clinical Pharmacology|September 8, 2017
Drug-drug interaction potential in men treated with enzalutamide: Mind the gapGuillemette Emma Benoist, Inge M van Oort, Stella Smeenk, et al.
British Journal of Clinical Pharmacology|August 26, 2021
The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancerEmmy Boerrigter, Guillemette E Benoist, Joanneke K Overbeek, et al.
Cancer Chemotherapy and Pharmacology|September 14, 2019
A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokineticsFloor J E Lubberman, Guillemette E Benoist, Winald Gerritsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 9, 2021
Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223Maarten J van der Doelen, Agnes Stockhaus, Yuanjun Ma, et al.
Nature Communications|April 24, 2023
In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcomeJeroen H A Creemers, Ankur Ankan, Kit C B Roes, et al.
Therapeutic Advances in Medical Oncology|December 17, 2024
Circulating tumor DNA-guided treatment decision in metastatic castration-resistant prostate cancer patients: a cost-effectiveness analysisCatharina J P Op 't Hoog, Sabien J E Bosman, Emmy Boerrigter, et al.
Non-Coding RNA|December 22, 2022
The Androgen Regulated lncRNA <i>NAALADL2-AS2</i> Promotes Tumor Cell Survival in Prostate CancerLevi Groen, Viktor Yurevych, Harshitha Ramu, et al.
Clinical Nuclear Medicine|November 23, 2017
223Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases: Lessons from Daily PracticeMaarten J van der Doelen, Malou C P Kuppen, Marianne A Jonker, et al.
BMJ Open|May 19, 2021
Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the 'trials within cohorts' study ProBCIAnke Richters, Richard P Meijer, Niven Mehra, et al.
Pageof 17